A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis associated interstitial lung disease
Recruiting
99 years and younger
All
Phase
3
1 Location
Brief description of study
Systemic sclerosis is a rare chronic autoimmune connective tissue disease. B cells have been reported to play a central role in the pathogenesis of SSc and B cell depletion has been shown to offer benefit to patients with SSc. Belimumab is a monoclonal antibody, which inhibits the survival of B cells. This study will assess whether treatment of SScILD patients with belimumab will result in the stabilization and/or improvement of lung
function.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855144
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
